CHMP adopted a positive opinion by consensus recommending an extension of indication for Opdivo for the treatment of adults and adolescents aged 12 years and older with previously untreated stage III or IV classical Hodgkin lymphoma based on study CA2098UT (SWOG 1826). (European Medicines Agency) - Oct 12, 2026 - CHMP Final Minutes of the
meeting on 20 - 23 Apr 2026: Sections 4.1, 4.2, 4.4, 4.8, and 5.1 of the
SmPC were updated, with corresponding revisions to the Package Leaflet. RMP
version 51.0 was also submitted, and the CHMP Assessment Report and translation
timetable were adopted.
CHMP • Classical Hodgkin Lymphoma • Hematological Malignancies • Oncology
|